TY - JOUR
T1 - Neuromyelitis optica spectrum disorders in Arabian Gulf (NMOAG); establishment and initial characterization of a patient registry
AU - with the Guthy-Jackson Charitable Foundation International Clinical Consortium
AU - Shosha, Eslam
AU - Al Asmi, Abdulla
AU - Nasim, Eman
AU - Inshasi, Jihad
AU - Abdulla, Fatima
AU - Al Malik, Yaser
AU - Althobaiti, Ahmed
AU - Alzawahmah, Mohamed
AU - Alnajashi, Hind A.
AU - Binfalah, Mohamed
AU - AlHarbi, Awad
AU - Thubaiti, Ibtisam A.
AU - Ahmed, Samar F.
AU - Al-Hashel, Jasem
AU - Elyas, Mortada
AU - Nandhagopal, Ramachandiran
AU - Gujjar, Arunodaya
AU - Harbi, Talal Al
AU - Towaijri, Ghadah Al
AU - Alsharooqi, Isa A.
AU - AlMaawi, Ahmed
AU - Al Khathaami, Ali M.
AU - Alotaibi, Naser
AU - Nahrir, Shahpar
AU - Al Rasheed, Abdulrahman A.
AU - Al Qahtani, Mohammed
AU - Alawi, Sadaga
AU - Hundallah, Khalid
AU - Jumah, Mohammed
AU - Alroughani, Raed
N1 - Funding Information:
Collaborators, *Guthy-Jackson International Clinical Consortium for NMOSD. Metha Appiwatanakul MD, Prasat Neurological Institute, Bangkok Thailand; Denis Bichuetti MD, Escola Paulista de Medicina-Universidade Federal de São Paulo, São Paulo, Brazil; Simon Broadley MD PhD, Griffith University, Queensland, Australia; Philippe Cabre MD, CHU Pierre Zobda Quitman, Martinique, French West Indies; Jerome De Seze MD PhD, CHU Strasbourg, Strasbourg, France; Guillermo Delgado-Garcia MD, National Institute of Neurology and Neurosurgery, Mexico City, Mexico; Joachim Havla MD, Ludwig Maximilians University, Munich, Germany; Jyh Yung Hor, MD, Penang General Hospital, Penang, Malaysia; Anu Jacob MD, The Walton Centre NHS Trust and University of Liverpool, Liverpool, UK; Najib Kissani MD, Mohamed VI University Hospital, Neuroscience Research Laboratory, Marrakech Medical School, Marrakech, Morocco; Marco Lana-Peixoto MD PhD, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Maria Isabel Leite MD D Phil, University of Oxford, Oxford UK; Michael Levy MD PhD, Massachusetts General Hospital, Charlestown, MA, USA; Ichiro Nakashima MD, Tohoku University, Sendai, Japan; Jacqueline Palace MD, Oxford University Hospital Trust, Oxford, UK; Friedemann Paul MD, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Neurocure Cluster of Excellence, NeuroCure Clinical Research Center, Berlin, Germany; Marius Ringelstein MD, Heinrich Heine University Düsseldorf, Düsseldorf, Germany; Terry J. Smith, University of Michigan, Ann Arbor, MI, USA; Pablo Villoslada MD, Stanford University, Stanford, CA, USA; Jens Würfel MD, MIAC AG, Basel, Switzerland; Michael R. Yeaman PhD, University of California, Los Angeles, CA, USA. We thank Dr. Eman Elsebaei for her statistical support, and Dr. Eman Farid for logistical support.
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2020/2
Y1 - 2020/2
N2 - Objective: To describe the clinical and radiological characteristics of neuromyelitis optica spectrum disorders (NMOSD) patients from the Arabian Gulf relative to anti-aquaporin 4 antibody serostatus. Methods: Retrospective multicentre study of hospital records of patients diagnosed with NMOSD based on 2015 International Panel on NMOSD Diagnosis (IPND) consensus criteria. Results: One hundred forty four patients were evaluated, 64.3% were anti-AQP4 antibody positive. Mean age at onset and disease duration were 31±12 and 7 ± 6 years respectively. Patients were predominantly female (4.7:1). Overall; relapsing course (80%) was more common than monophasic (20%). Optic neuritis was the most frequent presentation (48.6%), regardless of serostatus. The proportion of patients (54.3%) with visual acuity of ≤ 0.1 was higher in the seropositive group (p = 0.018). Primary presenting symptoms of transverse myelitis (TM) were observed in 29% of patients, and were the most significant correlate of hospitalization (p<0.001). Relative to anti-APQ4 serostatus, there were no significant differences in terms of age of onset, course, relapse rates or efficacy outcomes except for oligoclonal bands (OCB), which were more often present in seronegative patients (40% vs.22.5%; p = 0.054). Irrespective of serostatus, several disease modifying therapies were instituted including steroids or immunosuppressives, mostly, rituximab and azathioprine in the cohort irrespective of serostatus. The use of rituximab resulted in reduction in disease activity. Conclusion: This is the first descriptive NMOSD cohort in the Arabian Gulf region. Seropositive patients were more prevalent with female predominance. Relapsing course was more common than monophasic. However, anti-AQP4 serostatus did not impact disease duration, relapse rate or therapeutic effectiveness. These findings offer new insights into natural history of NMOSD in patients of the Arabian Gulf and allow comparison with patient populations in different World regions.
AB - Objective: To describe the clinical and radiological characteristics of neuromyelitis optica spectrum disorders (NMOSD) patients from the Arabian Gulf relative to anti-aquaporin 4 antibody serostatus. Methods: Retrospective multicentre study of hospital records of patients diagnosed with NMOSD based on 2015 International Panel on NMOSD Diagnosis (IPND) consensus criteria. Results: One hundred forty four patients were evaluated, 64.3% were anti-AQP4 antibody positive. Mean age at onset and disease duration were 31±12 and 7 ± 6 years respectively. Patients were predominantly female (4.7:1). Overall; relapsing course (80%) was more common than monophasic (20%). Optic neuritis was the most frequent presentation (48.6%), regardless of serostatus. The proportion of patients (54.3%) with visual acuity of ≤ 0.1 was higher in the seropositive group (p = 0.018). Primary presenting symptoms of transverse myelitis (TM) were observed in 29% of patients, and were the most significant correlate of hospitalization (p<0.001). Relative to anti-APQ4 serostatus, there were no significant differences in terms of age of onset, course, relapse rates or efficacy outcomes except for oligoclonal bands (OCB), which were more often present in seronegative patients (40% vs.22.5%; p = 0.054). Irrespective of serostatus, several disease modifying therapies were instituted including steroids or immunosuppressives, mostly, rituximab and azathioprine in the cohort irrespective of serostatus. The use of rituximab resulted in reduction in disease activity. Conclusion: This is the first descriptive NMOSD cohort in the Arabian Gulf region. Seropositive patients were more prevalent with female predominance. Relapsing course was more common than monophasic. However, anti-AQP4 serostatus did not impact disease duration, relapse rate or therapeutic effectiveness. These findings offer new insights into natural history of NMOSD in patients of the Arabian Gulf and allow comparison with patient populations in different World regions.
KW - Arabian Gulf
KW - Clinical phenotypes
KW - NMOSD
UR - http://www.scopus.com/inward/record.url?scp=85073733185&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073733185&partnerID=8YFLogxK
U2 - 10.1016/j.msard.2019.101448
DO - 10.1016/j.msard.2019.101448
M3 - Article
C2 - 32164911
AN - SCOPUS:85073733185
SN - 2211-0348
VL - 38
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
M1 - 101448
ER -